Table 1 Clinicopathological characteristics of patients undergoing LR for hepatic metastasis from CRC in different eras.
Characteristics | Era 1 n= 128 (%) | Era 2 n= 151 (%) | p value |
|---|---|---|---|
Age in years, median (range) | 59 (21-81) | 63 (29-88) | 0.009 |
Gender | Â | Â | 0.194 |
   Male | 76 (59.4) | 101 (66.9) |  |
   Female | 52 (40.6) | 50 (33.1) |  |
Primary tumor location | Â | Â | 0.112 |
   Colon | 65 (50.8) | 91 (60.3) |  |
   Rectum | 63 (49.2) | 60 (39.7) |  |
Liver metastasis | Â | Â | Â |
   CEA (mg/dL), median (range) | 15.5 (0.5-7025) | 12.4 (0.8-4280) | 0.743 |
Metastatic type | Â | Â | 0.471 |
   Synchronous | 85 (66.4) | 94 (62.3) |  |
   Metachronous | 43 (33.6) | 57 (37.7) |  |
Tumor number | Â | Â | < 0.0001 |
   Solitary | 97 (75.8) | 84 (55.6) |  |
   Multiple | 31 (24.2) | 67 (44.4) |  |
Maximum tumor size (cm) | Â | Â | 0.331 |
   < 5 | 108 (85.7) | 122 (81.3) |  |
   ≥5 | 20 (14.3) | 29 (18.7) |  |
Extent of liver resection | Â | Â | 0.209 |
   < 3 segments | 88 (68.8) | 114 (75.5) |  |
   ≥ 3 segments | 40 (31.2) | 37 (24.5) |  |
Perioperative chemotherapy | Â | Â | < 0.0001 |
   FU or with LV | 69 (54.0) | 8 (5.3) |  |
   FU/LV/oxaliplatin | 9 (7.0) | 36 (23.8) |  |
   FU/LV/irinotecan | 9 (7.0) | 67 (44.4) |  |
   Other regimens | 22 (17.2) | 30 (19.9) |  |
   No | 19 (14.8) | 10 (6.6) |  |
CRC recurrence | Â | Â | 0.008 |
   IHR | 57 (44.5) | 43 (28.4) |  |
   SR | 48 (37.5) | 62 (41.1) |  |
   No | 23 (18.0) | 46 (30.5) |  |
Resection of CRC recurrence | 10 (9.5)* | 31 (29.5)* | 0.003 |
Surgical mortality | 2 (1.6) | 2 (1.3) | 1.000 |